The United States is the largest national market for low molecular weight (LMW) heparin in North America, driven by the high burden of venous thromboembolism (VTE), deep vein thrombosis, pulmonary embolism, and acute coronary syndromes, along with an aging population and a large surgical and orthopedic patient base. Enoxaparin, dalteparin, and fondaparinux-class alternatives are widely used for...